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Abstract 
Our studies of Levantine viper venom have demonstrated that the venom is a rich source of biomedically important 
proteins and peptides. The venom contains metalloproteases: thrombolytic, fibrin-degrading lebetase, an endothelial cell 
apoptosis inducing metalloprotease (VLAIP), factor X activator (VLFXA); serine proteases: factor V activator, bradykinin-
releasing serine proteases, β-fibrinogenase, α-fibrinogenase and chymotrypsin-like protease and different other enzymes such as 
phosphodiesterase, 5`-nucleotidase, ribonuclease, phospholipase A2s and L-amino acid oxidase. Among nonenzymatic 
components venom contains: nerve growth factor, vascular endothelial growth factor, disintegrins, C-type lectins.  
 Here we report the isolation and characterization of proteins and peptides from Vipera lebetina venom using size 
exclusion, ion exchange, hydrophobic interaction and affinity chromatography, HPLC, UPLC and MALDI-TOF MS methods. N-
terminal sequences and internal sequences of tryptic peptides of different proteins were determined using Edman sequencing and 
LC-ESI-MS/MS techniques. On the basis of fragmental sequences of proteins the oligonucleotides were designed and used as 
primers for cDNA cloning. Using cDNA library of the venom gland of a single snake the cDNAs coding proteins were cloned 
and sequenced. Protein sequences were deduced from cDNA sequences. 
The substrate specificity of venom proteases against insulin B-chain, bradykinin, substance P, and 6-10 amino acid 
residues containing peptides synthesized according to potential cleavage regions of fibrinogen, factor X, factor IX, factor V, α2- 
macroglobulin bait region and pregnancy zone protein were studied using MALDI-TOF mass spectrometry technique. 
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1. Introduction 
Snake venoms are complex mixtures of pharmacologically active proteins and peptides. They can target different 
tissues, causing simultaneous changes of multiple physiological systems and, therefore, snake venom components 
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 may be useful candidates for therapeutic agents, for use in the diagnosis of several diseases and for understanding 
physiological and pathological processes in basic research.  
Our studies of Levantine viper venom have demonstrated that the venom is rich source of biomedically important 
proteins (e.g. factor V and X activators, fibrinolytic enzyme, disintegrins). The venom contains metalloproteases 
that all have a typical zinc chelating sequence (HEXXHGXXH) [1]: thrombolytic fibrin-degrading lebetase [2], an 
endothelial cell apoptosis inducing metalloprotease (VLAIP) [3], factor X activator (VLFXA) [4]. V. lebetina 
venom contains also different serine proteases: factor V activator (VLFVA) [5], bradykinin-releasing serine 
proteases, thermostable β-fibrinogenase, α-fibrinogenase (VLAF) [6] and chymotrypsin-like protease (VLCTLP) 
which has no homolog among known serine proteases. L-amino acid oxidase (LAAO) [7] and phospholipase A2s 
(VLPLA2) [8] besides their specific enzymatic activity inhibit platelet aggregation induced by ADP or collagen. 
Among nonenzymatic components venom contains nerve growth factor (NGF) [9], vascular endothelial growth 
factor (VEGF) [10], disintegrins [11-16], C-type lectins [17].  
Here we provide the complex block-scheme of the isolation and characterization of above mentioned proteins and 
peptides from Vipera lebetina venom using size exclusion, ion exchange, hydrophobic and affinity 
chromatographies, HPLC, UPLC, LC-ESI-MS/MS and MALDI-TOF MS methods. 
 
2. Methods 
 
 Protease activities were determined with azocasein and fibrinogen as substrates [18]. Fibrinolytic activity was 
assayed by fibrin plate technique [19]. Esterolytic activities were determined using ATEE and BAEE as substrates 
[20]. Phospholipase A2 activity was assayed by titrametric method using egg yolk phosphatidylcholine as a substrate 
[8]. LAAO activity was determined spectrophotometrically using the method modified from Bergmeyer [21]. 
Proteins and peptides were purified from crude V. lebetina venom (Tashkent Serpentarium, Uzbekistan) using the 
different purification schemes. The size exclusion, ion exchange, HPLC, UPLC and affinity columns were 
commercial. Purified proteins and peptides were analysed by SDS-PAGE, isoelectric focusing and MALDI-TOF 
MS. Fibrinogen degradation products were analysed by SDS-PAGE. N-terminal sequences and internal sequences 
of tryptic peptides of different purified proteins were determined using Edman sequencing and LC MS/MS 
technique. MALDI-TOF mass spectrometry analysis was used for the recovery and identification of the peptides 
released by trypsin hydrolysis using 2,5-dihydroxybenzoic acid as matrix. The MALDI-TOF mass spectra were 
measured with a home-built MALDI mass spectrometer designed for maximum flexibility in use [22]. All peptides 
were synthesized at the 100 µmol scale on Applied Biosystems 431A Peptide Synthesizer using BOC (t-butyl-
oxycarbonyl) chemistry as suggested by the manufacturer. The purity of peptides was assessed by HPLC and 
MALDI-TOF mass spectrometry. 
Platelet aggregation assays were performed in human platelet-rich plasma using a Chronolog aggregometer [18]. For 
detection of the NGF bioactivity, in vitro bioassay with rat PC12 pheochromocytoma cells (ATCC CRL-1721, 
USA) was used [23]. 
The cDNA library of the venom gland of a single adult Central Asian Vipera lebetina snake was constructed in the Uni-
ZAP XR [24] and was used as a source of the template. PCR was carried out in a Perkin Elmer Thermal Cycler 480. 
The clones were sequenced on Perkin Elmer ABI Prism Model 310 DNA Sequencer by cycle sequencing using ABI 
Prism Dye Terminator Cycle Sequencing Ready Reaction Kit with AmpliTaq DNA Polymerase.  
 
3. Results 
 
3.1. Purification of venom components  
 
For the first step of purification size-exclusion chromatography on Sephadex G-100sf column in the soft conditions 
(eluent: 0.2 M ammonium acetate) was used saving biological activities of venom components (Fig. 1). The first 
fraction contains VLFXA, VLAIP, nucleotidases, phosphodiesterase, L-amino acid oxidase and several unidentified 
components. β-Fibrinogenase, chymotrypsin-like protease (VLCTLP) and hyaluronidase are between the first and 
the second fraction. Factor V activator, α-fibrinogenase, nerve growth factor, vascular endothelial growth factor, 
dimeric disintegrins, phospholipase A2, C-type lectins are eluted in the second fraction. Lebetase isoforms are in the 
third fraction. The low-molecular mass fractions (IV and V) contain several peptides.  
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Fig. 1. Size-exclusion chromatography of V. lebetina venom. Crude venom (1.5 g) was dissolved in 10 ml of 0.2 
M ammonium acetate, pH 6.7. Insoluble material was removed by centrifugation (5000 x g for 15 min) and the 
supernatant was applied to the column (2.2 x 140 cm) of Sephadex G-100 superfine equilibrated with 0.2 M 
ammonium acetate. The elution was carried out with the same solution. The measured activities are shown with 
coloured lines (rhs – right-hand scale, lhs – left-hand scale). 
 
 
 
 
The individual proteins were obtained by combining different separation methods (Fig. 2). Here only a simplified 
block-scheme is presented; the detailed purifications of different proteins and peptides are described in our previous 
publications [3, 5, 7-9, 11, 25, 26].  
VEGF [10], lebein [12], lebestatin [13], C-type lectins [17] are purified and characterized in other laboratories. Here 
these components were localized in size exclusion chromatography fractions (Fig. 2) by tryptic peptide fragments 
using MALDI-TOF MS and the primary structure data provided in databases. 
 
0
2
4
6
8
10
12
14
16
50 100 150 200 250 300 350 400 450 500 550 600 650
volume, ml
O
D2
80
0,0
0,2
0,4
0,6
0,8
1,0
1,2
OD280, lhs
AC, OD390, rhs
BAEE, OD253, rhs
ATEE, OD237 x 2, rhs
I
 II
III
IV
 V
2010) 109–115 111J. Siigur et al. / Procedia Chemistry 2 (
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
                                                                           
I fraction 
VLFXA 
VLAIP 
5´-nucleotidase 
phosphomonoesterases 
phosphodiesterases  
LAAO 
 
between I-II 
fr. 
VLCTLP 
β-fibrinogenase 
hyaluronidase 
II fraction 
VLFVA 
kininogenase 
α-fibrinogenase 
NGF 
VEGF [10] 
viplebedin-2 
lebein [12] 
C-type lectins [17] 
VLPLA2 
III fraction 
lebetases 
 
IV fraction 
lebestatin [13] 
 
V fraction 
lebetins 
 
CM52 cellulose DE52 cellulose CM52 cellulose 
 
HPLC C18 HPLC C4 DE52 cellulose 
 
lebetases 
II-III fr. 
HPS-7 HPLC TSK 
DEAE 
Heparin 
agarose 
Heparin agarose 
 
viplebedin-2 VLPLA2s 
I fr. II fr. II fr. II fr. VI fr. V-VI fr. 
DE52 
CM52 
VLAIP VLFXA 
FPLC 
Superdex 75 
VLCTLP LAAO 
I fr. 
I fr. 
III fr. 
II fr. 
I fr. 
VLFVA 
I fr. 
UPLC C4 
III fr. 
NGF 
Size-exclusion chromatography on Sephadex G-100sf of Vipera lebetina venom 
 
 Fig. 2. The block-scheme of separation of proteins and peptides from Vipera lebetina venom. The detailed 
purification conditions are described in our previous publications: LAAO [7], VLAIP [3], VLFXA [25], VLFVA 
[5], NGF [9], viplebedin-2 [11], VLPLA2 [8], lebetase [26]. Size-exclusion chromatography - green boxes; ion-
exchange chromatography - blue boxes; HPLC and UPLC - pink boxes; affinity chromatography - yellow boxes. 
 
3.2. Specificity studies of proteases 
 
MALDI-TOF mass spectrometry technique was used for the discovery and identification of peptides released by 
protease hydrolysis (Fig. 3A,B; Fig. 4 A,B). The activity of snake venom proteases against bradykinin, substance P, 
insulin B-chain and 6-10 amino acid residues containing peptides synthesized according to potential cleavage 
regions of fibrinogen, factor X, factor IX, factor V, α2- macroglobulin bait region and pregnancy zone protein (PZP) 
was examined. Lebetase and VLAIP cleavage sites in different peptides are presented in Table 1. Thrombolytic 
enzyme lebetase cleaves bradykinin at the position Pro7-Phe8, as well as the other metalloprotease VLAIP does 
(Table 1). Cleavage of bradykinin by lebetase (an important side effect of the enzyme) destroys its biological 
activity. Viperidae venoms contain several serine proteases that release bradykinin and metalloproteases that cleave 
bradykinin, therefore the detection of bradykinin-releasing enzymes without metalloprotease inhibitors in crude 
venom is inadequate.  
Insulin B chain is widely used for specificity studies of different proteases: Ala14-Leu15 bond is cleaved by 
lebetase and VLAIP, Tyr16-Leu17 bond is cleaved by serine proteases VLCTLP and VLAF, but also by lebetase. 
VLAF hydrolyses Phe24-Phe25 and Phe25-Tyr26 bonds. VLCTLP also hydrolyses Phe25-Tyr26 bond but not Phe24-
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Phe25 bond (see Scheme 1). The sensitive and quick MALDI-TOF mass spectrometry methodology allows us to 
obtain the primary information about the substrate specificity of different proteases against various peptides and 
proteins. 
 
Table 1. Hydrolysis of peptide substrates by lebetase and VLAIP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1, Cleavage sites of oxidized insulin B chain by Vipera lebetina proteases. 
 
F1V2N3Q4H5L6C(SO3H)7G8S9H10L11V12E13A14L15Y16L17V18C(SO3H)19G20E21R22G23F24F25Y26T27P28K29A30 
                    ↑ ↑           ↑ ↑ ↑   
       VLAIP                  VLAF VLCTLP 
  
                                 VLCTLP 
                lebetase VLAF                      VLAF 
        lebetase 
Name of substrate 
  
Lebetase cleavage sites [22] 
 
VLAIP cleavage sites [3] 
  
Substance P  
RPKPQQFFGLM 
  
Pro4-Gln5 
Gly9-Leu10 
Pro2-Lys3 
Gln5-Gln6 
Phe7-Phe8 
Gly9-Leu10 
Bradykinin 
 RPPGFSP↓FR 
  
 Pro7-Phe8 
  
Pro7-Phe8 
  
Fibrinogen fragment 406-417 
HTEK↓LVTS 
  
  
Lys4-Leu5 
  
  
Lys4-Leu5 
  
 
α2-M fragment 693-700   
GHAR↓LVHV 
  
 
Arg4-Leu5 
  
Arg4-Leu5 
  
PZP fragment 686-693  
PYVP↓QLGT 
  
 
Pro5-Gln6 
  
Pro5-Gln6 
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Fig. 3A. Mass spectrum of human factor V peptide fragment 1543-1549. 
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Fig. 3B. Mass spectrum of cleavage products of human factor V peptide fragment 1543-1549 after treating with 
VLFVA. Matrix: 2,5-dihydroxybenzoic acid. 
 
      
3.3. Structural studies 
 
 N-terminal sequences and internal sequences of tryptic peptides of purified proteins were determined using 
Edman sequencing and LC MS/MS technique. On the basis of fragmental sequences of proteins the oligonucleotides 
were designed and were used as primers for cDNA cloning. Using cDNA library of the venom gland of a single V. 
lebetina snake the proteins coding cDNAs were cloned and sequenced. The protein sequences were deduced from 
cDNA sequences. The deduced protein sequences are registered under following accession numbers: lebetases 
CAA66471; AAY45880; VLFXA chains: AAQ17467; AAQ17468; AAT91068; VLAIP chains: AAX38181; 
AAX38182; VLFVA AAF03233; VLAF AAM96674; VLPLA2s: ACQ57801; ACB59359; disintegrins: ABC18317; 
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ABC00778; NGF AAV64846. Vipera lebetina venom contains all types of reprolysins - metalloproteases that all 
have a typical zinc chelating sequence (HEXXHGXXH) [1] and monomeric and dimeric disintegrins that are 
studied by different research groups [11-16]. Better knowledge of the structural features of venom proteins allows us 
to consider the use of snake venom components as models for therapeutic agents and as tools in biochemical 
research to study cellular processes. 
 
4. Conclusions 
 
• Biomedically important proteins and peptides (VLFXA and VLFVA are diagnostic agents; lebetase is an 
effective fibrinolytic enzyme; VLAIP is an apoptosis inducing metalloproteinase; disintegrins are potential 
anticancer agents; growth factors NGF and VEGF; antimicrobial LAAO; platelet aggregation inhibiting 
PLA2s) were isolated from Vipera lebetina venom using size exclusion, ion exchange, hydrophobic 
interaction and affinity chromatography, HPLC and UPLC methods.  
• A new serine protease from V. Lebetina venom having ChymoTrypsin Like Proteolytic activity 
(VLCTLP) was purified and characterized. It is the only known enzyme from snake venoms that catalyses 
acetyltyrosine ethyl ester hydrolysis. 
• MALDI-TOF MS is effective tool for detection of protein and peptide molecular masses and for studying 
of proteolysis degradation products. 
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